Physician profile
Mark Nyitray
NPI 1467457689
$5,494.11
in general payments reported to CMS, 2019-2025
27 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $217 · 2021: $880 · 2022: $1,530 · 2023: $894 · 2024: $521 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.63 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,486.64 | 2019-2025 | |
| Janssen Biotech, INC. | $587.88 | 2021-2025 | Tremfya, Stelara, Simponi |
| Intercept Pharmaceuticals, INC. | $521.42 | 2019-2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $469.81 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $304.47 | 2019-2023 | Rebyota, Clenpiq |
| Nestle Healthcare Nutrition INC. | $275.11 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $267.14 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $240.60 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.95 | 2020-2023 | Xifaxan |
| Ardelyx, INC. | $172.84 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $150.05 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $142.91 | 2019-2024 | Kristalose |
| Redhill Biopharma INC. | $140.72 | 2021-2022 | |
| Daiichi Sankyo INC. | $86.24 | 2020-2021 | |
| Braintree Laboratories, INC. | $80.86 | 2021-2025 | Suflave, Sutab |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75.30 | 2021-2022 | |
| Pfizer INC. | $63.20 | 2023-2025 | |
| Celgene Corporation | $45.99 | 2021-2022 | |
| Evoke Pharma, INC. | $41.95 | 2021 | |
| Capsovision, INC. | $31.57 | 2023-2024 | Capsocam Plus |
| Allergan, INC. | $26.23 | 2019 | |
| Ucb, INC. | $23.87 | 2019 | |
| Genzyme Corporation | $23.07 | 2023 | |
| Concordia Pharmaceuticals INC. | $20.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.36 | 2025 | Dupixent |
| Alfasigma USA, INC. | $14.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nyitray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.